Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment

Objectives. In Erdheim-Chester disease (ECD), the empirical single dose (SD, 100 mg/day) anakinra sometimes induces only partial responses. Since SD is usually well tolerated, doubling the dose might improve response while maintaining an acceptable safety profile. Methods. A retrospective analysis w...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Fréderic Franconieri, Samuel Deshayes, Hubert de Boysson, Salim Trad, Nicolas Martin Silva, Benjamin Terrier, Boris Bienvenu, Françoise Galateau-Sallé, Jean-François Emile, Alison C. Johnson, Achille Aouba
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2018-08-01
Edice:	OncoImmunology
Témata:	erdheim-chester disease anakinra braf mutation nras mutation vemurafenib
On-line přístup:	http://dx.doi.org/10.1080/2162402X.2018.1450712
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!